A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United Kingdom

Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge

Tayside Medical Science Centre, Ninewells Hospital & Medical School, Dundee

NHS Lothian, Edinburgh

Glasgow Royal Infirmary, Glasgow

The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds

Royal Bromptom Hospital (NHS Guy's and Thomas'), London

Manchester University NHS Foundation Trust, Manchester

Medicines Evaluation Unit (MEU), Manchester

University Hospital Southampton NHS Foundation Trust, Southampton